Reactive TDM is currently considered as standard of care, whereas proactive TDM is
emerging as a new therapeutic strategy for better optimizing anti-TNF therapy in IBD …

Background: Therapeutic drug monitoring (TDM) is a decision-making tool for optimizing the
use of certain therapies. In this article, the authors review the role of proactive TDM of …

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is increased in
inflammatory bowel disease (IBD) patients, and its serum levels correlate with a worse …

Background: Biologic medications are recommended for treatment of moderately-to-severely
active Crohn disease (CD) or ulcerative colitis (UC) in children. However, many patients …

Objectives To study infliximab (IFX) pharmacokinetics in children with inflammatory bowel
disease (IBD) during induction therapy to predict outcome and explore if other covariates …

Background Very few data regarding the use of infliximab in children with very early-onset
inflammatory bowel disease (VEO-IBD) have been reported. Objective We aimed to assess …

Introduction: Adalimumab is effective in inducing and maintaining remission in children with
inflammatory bowel diseases (IBD). Therapeutic drug monitoring is an important strategy to …

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that is characterized by
transmural inflammation that can affect any part of the gastrointestinal tract, leading to …

Infliximab is commonly used in inflammatory bowel disease (IBD), however, differences in
clinical response among patients are common. Several studies have considered the …

Introduction: Medical treatment of pediatric inflammatory bowel diseases (IBD) has been
greatly changed by the introduction of a number of biologic agents that are able to target …